Biogen Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Biogen Inc Unternehmen

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Unternehmensinformationen

Unternehmens-codeBIIB

Name des UnternehmensBiogen Inc

IPO-datumSep 17, 1991

Gegründet am1997

CEOMr. Christopher A. (Chris) Viehbacher

Anzahl der mitarbeiter7605

WertpapierartOrdinary Share

GeschäftsjahresendeSep 17

Addresse225 Binney Street

StadtCAMBRIDGE

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl02142

Telefon17814642000

Websitehttps://www.biogen.com/

Unternehmens-codeBIIB

IPO-datumSep 17, 1991

Gegründet am1997

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.88K

+36.82%

Mr. Jesus B. Mantas

Independent Director

6.43K

+26.34%

Dr. Maria C. Freire, Ph.D.

Independent Director

3.48K

+62.47%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

1.90K

+187.01%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Umsatzaufteilung

Währung: USDUpdate-Zeit: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

Nach RegionUSD

Name

Umsatz

Anteil

Rest of World

3.98B

41.09%

United States

3.30B

34.08%

United states-Revenues from anti-CD20 therapeutic

1.75B

18.09%

Rest of World-Other revenues

652.60M

6.74%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

Aktionäre

Update-Zeit: Fri, Feb 21

Aktionärsstatistik

Art

Aktionärsstatistik

Aktionäre

Anteil

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Aktionärsstatistik

Aktionäre

Anteil

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Art

Aktionäre

Anteil

Investment Advisor

43.69%

Investment Advisor/Hedge Fund

36.85%

Hedge Fund

5.46%

Research Firm

2.82%

Pension Fund

2.29%

Bank and Trust

1.74%

Sovereign Wealth Fund

1.67%

Private Equity

0.35%

Individual Investor

0.15%

Other

4.99%

Institutionelle Beteiligung

Update-Zeit: Mon, Jan 20

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

2074

138.81M

94.83%

-5.05M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

2022Q4

2292

132.00M

91.64%

-4.78M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

16.68M

11.39%

+1.13K

+0.01%

Dec 31, 2024

PRIMECAP Management Company

16.05M

10.96%

-268.87K

-1.65%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.59M

5.87%

+23.69K

+0.28%

Dec 31, 2024

State Street Global Advisors (US)

7.40M

5.05%

+53.29K

+0.73%

Dec 31, 2024

Wellington Management Company, LLP

4.93M

3.37%

-200.47K

-3.91%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.70M

2.52%

+82.46K

+2.28%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

3.10M

2.12%

-1.16M

-27.17%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

3.01M

2.06%

+40.53K

+1.36%

Feb 28, 2025

Pacer Advisors, Inc.

2.67M

1.82%

+2.65M

+13.57K%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Verbundene ETFs

Update-Zeit: Sun, Apr 6

Name

Anteil

Invesco Biotechnology & Genome ETF

4.41%

iShares Neuroscience and Healthcare ETF

3.82%

Global X US Cash Flow Kings 100 ETF

3.55%

VanEck Biotech ETF

3.23%

Tema Neuroscience and Mental Health ETF

3.15%

Alger Russell Innovation ETF

3.04%

First Trust NYSE Arca Biotechnology Index Fund

2.94%

First Trust NASDAQ Pharmaceuticals ETF

2.89%

Invesco Pharmaceuticals ETF

2.39%

SPDR S&P Biotech ETF

2.19%

Invesco Biotechnology & Genome ETF

Anteil4.41%

iShares Neuroscience and Healthcare ETF

Anteil3.82%

Global X US Cash Flow Kings 100 ETF

Anteil3.55%

VanEck Biotech ETF

Anteil3.23%

Tema Neuroscience and Mental Health ETF

Anteil3.15%

Alger Russell Innovation ETF

Anteil3.04%

First Trust NYSE Arca Biotechnology Index Fund

Anteil2.94%

First Trust NASDAQ Pharmaceuticals ETF

Anteil2.89%

Invesco Pharmaceuticals ETF

Anteil2.39%

SPDR S&P Biotech ETF

Anteil2.19%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Biogen Inc

118.840USD

Biogen Inc

118.840

Übersicht

Unternehmen